Fundz
Real-time · AI · Cross-signal

Candid Therapeutics just raised. Here's exactly what to do next.

Who to reach, what to say, and why now — on Candid Therapeutics, plus every funding round, exec hire, and M&A move that follows. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your planRequest a demo

Everyone else gives you a piece

✕Crunchbase & PitchBook list the company — No person, no timing, no opener.
✕ZoomInfo & Apollo sell you a contact — No trigger, no reason to reach out now.
✕LinkedIn Sales Navigator shows you people — No real-time signal, no opener.
✕Clay enriches lists you built — No live signal of its own, no who or when.
✕ChatGPT & gen-AI tools answer on a delay — No live data, no verified contact.
Who to contactWhat to sayWhen to reach outWhy now

Only Fundz delivers all four.

Candid Therapeutics raised $370M in a Series A funding round to develop antibody drugs for inflammatory diseases.

RECENTLY ACQUIREDSep 09, 2024•over 1 year ago

Amount Raised

$370 Million

Round Type

series a

San DiegoBiotechnologyHealth CareTherapeutics

Description

Candid Therapeutics, a new biotech company, secured over $370 million in funding to develop treatments for autoimmune diseases. The funding will allow them to operate for several years and explore opportunities for an initial public offering.

Company Information

Company

Candid Therapeutics

Location

San Diego, California, United States

About

Candid Therapeutics is a biotechnology startup focused on developing antibody drugs specifically for inflammatory diseases. The company has raised over $370 million in funding and has acquired rights to innovative drug candidates that target T cells. Candid aims to leverage its expertise to advance clinical trials in autoimmune conditions. The company's strategy highlights the potential of T-cell engagers as a more viable solution compared to traditional cell therapies.

Related People

Suggested for you
1 contact

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Candid Therapeutics's next move

Learn about Strategic plan

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.

Watching Candid Therapeutics? See every signal — funding, hires, M&A, contracts, sentiment.

Request a demoChoose your plan